Geron Corporation, a late-stage clinical biopharmaceutical company, announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to participate in fireside chats at following investor conferences.
- 22nd Annual Needham Virtual Healthcare Conference
Thursday, April 20 at 10:15 a.m. ET
- Stifel 2023 Virtual Targeted Oncology Days
Tuesday, April 25 at 2:00 p.m. ET
A webcast of each fireside chat and corporate presentation will be available through the Investor Relations section of Geron’s website under Events. Following each scheduled conference event, the related webcast will be archived and available for replay for a period of 30 days.
About Geron
Geron is a late-stage biopharmaceutical company pursuing therapies with the potential to extend and enrich the lives of patients living with hematologic malignancies. Its investigational first-in-class telomerase inhibitor, imetelstat, harnesses Nobel Prize winning science in a treatment that may alter the underlying course of these diseases. To learn more, visit http://www.geron.com/or follow us on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230412005663/en/
Aron Feingold
Investor and Media Relations
investor@geron.com
media@geron.com
Source: Geron Corporation
View this news release online at:
http://www.businesswire.com/news/home/20230412005663/en
